Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Non-Hodgkin B-cell Lymphoma

NCT04148742 is registered in ClinicalTrials.gov with Dizal Pharmaceuticals as lead sponsor.

NCT NCT04148742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04148742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Non-Hodgkin B-cell Lymphoma
Lead sponsor
Dizal Pharmaceuticals
Phase
Phase 1/2
Overall status
Withdrawn
Start date
August 31, 2021
Completion date
July 31, 2023
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's b-cell lymphoma